A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
2015; Elsevier BV; Volume: 126; Issue: 5 Linguagem: Inglês
10.1182/blood-2015-01-620302
ISSN1528-0020
AutoresGiovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, Julian D. Gillmore, Andrea Foli, Helen J. Lachmann, Marco Basset, Philip N. Hawkins, Giampaolo Merlini, Ashutosh D. Wechalekar,
Tópico(s)Myeloproliferative Neoplasms: Diagnosis and Treatment
ResumoKey Points CyBorD achieves excellent outcome in noncardiac patients with AL amyloidosis and can rescue subjects with reversible heart damage. The outcome of high-risk patients remains poor, but response to CyBorD can also improve survival in this group.
Referência(s)